Invivoscribe Expands Ion PGM(TM) NGS Platform Menu: Releases Additional CE-IVD Clonality Kits with Bioinformatics Software and RUO Kits with MRD Software
28 févr. 2017 06h00 HE
|
Invivoscribe Technologies Inc.
SAN DIEGO, CA--(Marketwired - Feb 28, 2017) - Invivoscribe® Technologies Inc., a global company with more than 20 years of experience providing clonality and biomarker test solutions for the...
German Supreme Court Upholds and Strengthens Invivoscribe FLT3 Patent Position
29 mars 2016 08h00 HE
|
Invivoscribe Technologies, Inc.
SAN DIEGO, CA--(Marketwired - Mar 29, 2016) - In a landmark patent decision that will accelerate approval of new drugs and improve treatment of patients with acute myeloid leukemia (AML), the...
Invivoscribe Announces Long-Term Collaboration to Develop Immuno-Oncology Tests With Thermo Fisher Scientific
10 févr. 2016 08h00 HE
|
Invivoscribe Technologies, Inc.
SAN DIEGO, CA--(Marketwired - Feb 10, 2016) - Invivoscribe® Technologies, Inc., a global company that provides international access to personalized molecular diagnostics, today announces it...
Invivoscribe Technologies Announces Companion Diagnostic Agreement
28 avr. 2015 08h07 HE
|
Invivoscribe Technologies, Inc.
SAN DIEGO, CA--(Marketwired - Apr 28, 2015) - Invivoscribe® Technologies, Inc., a company with international experience commercializing in vitro diagnostic tests and developing companion...
Invivoscribe(R) Launches Four CE-Marked NGS-Based LymphoTrack(R) Dx Assays
21 avr. 2015 08h07 HE
|
Invivoscribe Technologies, Inc.
SAN DIEGO, CA--(Marketwired - Apr 21, 2015) - Invivoscribe Technologies, Inc. (IVS) announced today the commercial release of four CE-marked LymphoTrack® Dx next-generation sequencing (NGS)...
Genection Announces Launch of MyAML(TM), a Next Generation Sequencing (NGS) Assay for Acute Myeloid Leukemia
17 mars 2015 06h00 HE
|
Invivoscribe Technologies, Inc.
SAN DIEGO, CA--(Marketwired - Mar 17, 2015) - Genection™, Inc., a subsidiary of Invivoscribe Technologies®, Inc., announced today that it has launched MyAML™, a CLIA validated next...
Takara Bio Grants Patent License to Invivoscribe Technologies for FLT3-ITD Testing in Japan
05 déc. 2012 08h38 HE
|
Invivoscribe Technologies, Inc.
SAN DIEGO, CA--(Marketwire - Dec 5, 2012) - Invivoscribe Technologies, Inc. (San Diego, California) announced today that it has entered into an agreement with Takara Bio, Inc. (Otsu, Shiga, Japan)...